Carl P. Sparrow

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

24

H-Index

1

About

Carl P. Sparrow has made pivotal contributions to cardiovascular and lipid metabolism research, with a particular focus on endothelial lipase (EL) and its role in high-density lipoprotein (HDL) cholesterol regulation. His work has been instrumental in advancing our understanding of how EL activity influences HDL levels in vivo, a critical factor in cardiovascular disease risk. Sparrow is best known for developing fluorogenic substrates that enable high-throughput measurements of endothelial lipase activity, as detailed in his highly cited 2006 paper (24 citations). This methodological breakthrough has been essential for the discovery of small molecule inhibitors that specifically target EL, opening new avenues for therapeutic intervention in dyslipidemia. By creating robust, sensitive assays, Sparrow has empowered researchers to screen for potential drug candidates efficiently, bridging the gap between basic enzymology and translational pharmacology. His work continues to shape the field of lipoprotein metabolism, providing tools and insights that are widely used by laboratories studying HDL biology and cardiovascular therapeutics.

Research Focus

Key Achievements

1
H-Index
1
Papers
24
Total Citations
24
Avg Citations/Paper
🏆 Most Cited Paper
Fluorogenic substrates for high-throughput measurements of endothelial lipase activity
24 citations · 2006
📈 Most Prolific Year: 2006 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago